Alkermes (ALKS) News Today → Trump Reveals Conspiracy Behind Fed-Controlled Digital Currency. (From Monetary Gold) (Ad) Free ALKS Stock Alerts $24.49 -0.22 (-0.89%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 7:00 AM | prnewswire.comAlkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific ConferencesMay 14 at 4:25 AM | marketbeat.comRussell Investments Group Ltd. Sells 81,673 Shares of Alkermes plc (NASDAQ:ALKS)Russell Investments Group Ltd. cut its stake in Alkermes plc (NASDAQ:ALKS - Free Report) by 43.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 105,357 shares of the company's stock after selling 81,6May 13 at 10:07 AM | marketbeat.comAlkermes plc (NASDAQ:ALKS) Shares Sold by Teacher Retirement System of TexasTeacher Retirement System of Texas lowered its position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 31.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 452,217 shares of the company's stock after selling 206,144 shares during theMay 9, 2024 | marketbeat.comLSV Asset Management Buys Shares of 117,000 Alkermes plc (NASDAQ:ALKS)LSV Asset Management purchased a new position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 117,000 shares of the company's stock, valued at approximateMay 8, 2024 | marketbeat.comMaryland State Retirement & Pension System Buys Shares of 60,652 Alkermes plc (NASDAQ:ALKS)Maryland State Retirement & Pension System bought a new position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 60,652 shares of thMay 6, 2024 | americanbankingnews.comAlkermes plc (NASDAQ:ALKS) Expected to Post Q1 2025 Earnings of $0.43 Per ShareMay 5, 2024 | americanbankingnews.comStockNews.com Downgrades Alkermes (NASDAQ:ALKS) to HoldMay 3, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Hold Rating on Alkermes (ALKS)May 2, 2024 | markets.businessinsider.comAlkermes Buy Rating Affirmed on Strong Commercial Performance and Promising Drug PipelineMay 2, 2024 | markets.businessinsider.com7 Analysts Assess Alkermes: What You Need To KnowMay 2, 2024 | marketbeat.comAlkermes (NASDAQ:ALKS) Earns "Neutral" Rating from HC WainwrightHC Wainwright restated a "neutral" rating and issued a $35.00 target price on shares of Alkermes in a research note on Thursday.May 2, 2024 | markets.businessinsider.comMaintaining Hold on Alkermes Amidst Modest Q1 Performance and Pipeline ProspectsMay 2, 2024 | markets.businessinsider.comAlkermes Hold Rating Justified by Mixed Financial Performance and Uncertain Pipeline ProspectsMay 2, 2024 | marketbeat.comAlkermes (NASDAQ:ALKS) Releases Quarterly Earnings Results, Misses Expectations By $0.15 EPSAlkermes (NASDAQ:ALKS - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $0.43 EPS for the quarter, missing analysts' consensus estimates of $0.58 by ($0.15). Alkermes had a return on equity of 16.10% and a net margin of 21.39%. The company had revenue of $350.37 million for the quarter, compared to analysts' expectations of $360.26 million. During the same quarter in the previous year, the business posted ($0.10) EPS. The business's quarterly revenue was up 21.8% compared to the same quarter last year.May 2, 2024 | prnewswire.comAlkermes plc Completes Sale of Athlone, Ireland Facility to Novo NordiskMay 1, 2024 | investorplace.comALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024May 1, 2024 | seekingalpha.comAlkermes plc 2024 Q1 - Results - Earnings Call PresentationMay 1, 2024 | markets.businessinsider.comAlkermes plc Q1 Earnings SummaryMay 1, 2024 | marketbeat.comAlkermes (NASDAQ:ALKS) Updates FY 2024 Earnings GuidanceAlkermes (NASDAQ:ALKS) updated its FY 2024 earnings guidance. The company provided EPS guidance of 2.800-2.800 for the period, compared to the consensus estimate of 2.740. The company also issued revenue guidance of $1.5 billionillion-$1.6 billionillion, compared to the consensus estimate of $1.5 billionillion.May 1, 2024 | prnewswire.comAlkermes plc Reports First Quarter 2024 Financial ResultsMay 1, 2024 | marketbeat.comYousif Capital Management LLC Takes Position in Alkermes plc (NASDAQ:ALKS)Yousif Capital Management LLC acquired a new stake in shares of Alkermes plc (NASDAQ:ALKS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 83,397 shares of the company's stock, valued at approximately $2,313,000. A numApril 30, 2024 | marketbeat.comAlkermes plc (NASDAQ:ALKS) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Alkermes plc (NASDAQ:ALKS - Get Free Report) have earned an average rating of "Moderate Buy" from the ten brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendationApril 30, 2024 | benzinga.comAlkermes Stock (NASDAQ:ALKS), Quotes and News SummaryApril 27, 2024 | marketbeat.comSector Gamma AS Invests $5.55 Million in Alkermes plc (NASDAQ:ALKS)Sector Gamma AS bought a new position in Alkermes plc (NASDAQ:ALKS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 200,000 shares of the company's stock, valued at approximately $5,548April 26, 2024 | marketbeat.comAlkermes plc (NASDAQ:ALKS) Shares Acquired by Handelsbanken Fonder ABHandelsbanken Fonder AB lifted its stake in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 521.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 175,200 shares of the company's stock after purchasing an additional 14April 24, 2024 | finance.yahoo.comAlkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1April 19, 2024 | marketbeat.comAlkermes (NASDAQ:ALKS) Given "Neutral" Rating at HC WainwrightHC Wainwright reaffirmed a "neutral" rating and set a $35.00 price target on shares of Alkermes in a research note on Friday.April 18, 2024 | marketbeat.comMutual of America Capital Management LLC Has $3.33 Million Position in Alkermes plc (NASDAQ:ALKS)Mutual of America Capital Management LLC raised its position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 87.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 119,976 shares of the company's stApril 17, 2024 | prnewswire.comAlkermes to Report First Quarter Financial Results on May 1, 2024April 17, 2024 | marketbeat.comAlkermes (NASDAQ:ALKS) Shares Up 2.9%Alkermes (NASDAQ:ALKS) Trading 2.9% HigherApril 17, 2024 | finance.yahoo.comAlkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseApril 17, 2024 | marketbeat.comLouisiana State Employees Retirement System Invests $2.32 Million in Alkermes plc (NASDAQ:ALKS)Louisiana State Employees Retirement System bought a new position in Alkermes plc (NASDAQ:ALKS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 83,500 shares of the company's stock, valued at approximateApril 12, 2024 | marketbeat.comHardman Johnston Global Advisors LLC Sells 131,809 Shares of Alkermes plc (NASDAQ:ALKS)Hardman Johnston Global Advisors LLC lessened its stake in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,476,255 sharApril 12, 2024 | markets.businessinsider.comHold Rating on Alkermes Amid Promising ALKS 2680 Data and Regulatory ChallengesApril 12, 2024 | marketbeat.comQ3 2025 Earnings Forecast for Alkermes plc Issued By Zacks Research (NASDAQ:ALKS)Alkermes plc (NASDAQ:ALKS - Free Report) - Equities research analysts at Zacks Research upped their Q3 2025 earnings estimates for shares of Alkermes in a research note issued on Wednesday, April 10th. Zacks Research analyst R. Department now expects that the company will earn $0.52 per share forApril 11, 2024 | investing.comJefferies raises Alkermes stock target on positive OX2 dataApril 11, 2024 | marketbeat.comFY2027 EPS Estimates for Alkermes plc (NASDAQ:ALKS) Decreased by Leerink PartnrsAlkermes plc (NASDAQ:ALKS - Free Report) - Research analysts at Leerink Partnrs dropped their FY2027 earnings per share (EPS) estimates for shares of Alkermes in a research note issued to investors on Tuesday, April 9th. Leerink Partnrs analyst M. Goodman now expects that the company will post eaApril 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alkermes on Promising ALKS 2680 Clinical Trial Results and Growth PotentialApril 9, 2024 | markets.businessinsider.comBreaking Down Alkermes: 5 Analysts Share Their ViewsApril 9, 2024 | msn.comAlkermes posts early-stage win for sleeping disorder therapy (update)April 9, 2024 | seekingalpha.comAlkermes: Waking Up Narcolepsy Treatment With Promising Trial DataApril 9, 2024 | msn.comAlkermes succeeds in early-stage trial for sleeping disorder therapyApril 9, 2024 | marketbeat.comAlkermes (NASDAQ:ALKS) PT Raised to $50.00Jefferies Financial Group increased their target price on Alkermes from $42.00 to $50.00 and gave the company a "buy" rating in a report on Tuesday.April 9, 2024 | marketbeat.comAlkermes (NASDAQ:ALKS) Shares Gap Up to $25.93Alkermes (NASDAQ:ALKS) Shares Gap Up to $25.93April 9, 2024 | seekingalpha.comAlkermes plc: Collecting The Fruits Of The 2023 SpinoffApril 9, 2024 | prnewswire.comAlkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic HypersomniaApril 8, 2024 | prnewswire.comAlkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research SocietyApril 5, 2024 | marketbeat.comAssenagon Asset Management S.A. Buys New Shares in Alkermes plc (NASDAQ:ALKS)Assenagon Asset Management S.A. bought a new stake in Alkermes plc (NASDAQ:ALKS - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 73,170 shares of the company's stock, valued at approximately $2,030,000. Other heApril 4, 2024 | marketbeat.comState of Alaska Department of Revenue Takes $2.85 Million Position in Alkermes plc (NASDAQ:ALKS)State of Alaska Department of Revenue purchased a new position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 102,665 shares ofApril 1, 2024 | marketbeat.comRedwood Investments LLC Sells 319,609 Shares of Alkermes plc (NASDAQ:ALKS)Redwood Investments LLC trimmed its position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 73.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 115,979 shares of the company's stock after selling Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (Ad)The AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016. Get the full story here. ALKS Media Mentions By Week ALKS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALKS News Sentiment▼1.480.56▲Average Medical News Sentiment ALKS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALKS Articles This Week▼86▲ALKS Articles Average Week Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Madrigal Pharmaceuticals News Amicus Therapeutics News Geron News Ionis Pharmaceuticals News Agios Pharmaceuticals News Dynavax Technologies News Ligand Pharmaceuticals News Ironwood Pharmaceuticals News Pacira BioSciences News MannKind News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALKS) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill Publishingis this a buy and hold stock?Tips4TradersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
